It was a rocky week on Wall Street, with Nasdaq stocks inching lower and the Dow inching higher, but there were plenty of stocks really making some serious moves. Let's take a closer look at five of this past week's biggest scorchers.


May 9

Weekly Gain

RadNet (RDNT -0.48%)



Electronic Arts (EA 0.08%)



Keurig Green Mountain (GMCR.DL)



Ampio Pharmaceuticals (AMPE 9.23%)



InterMune (ITMN.DL)



Source: Barron's.

Let's start with RadNet. The provider of MRIs and PET/CT scans has been one of this year's biggest winners, and it padded those gains after posting better-than-expected bottom-line results. Revenue came in lighter than expected as the weather kept patients away from RadNet's centers, but its deficit was half as bad as analysts were forecasting. RadNet went on to raise its full-year EBITDA and free cash flow guidance, and at least one analyst followed suit. 

Deutsche Bank raised its price target from $5 to $7 after the report. How big has 2014 been for RadNet? The stock has soared 288% so far this year.

Electronic Arts was "in the game" as the country's second largest video-game publisher posted encouraging financials results. EA's adjusted profit of $0.48 a share, more than four times the $0.11 the pros were projecting. EA credits its success to the success of Titanfall, Battlefield 4, and FIFA 14

Keurig Green Mountain came through with another blowout quarter, with sales rising 10% to top $1.1 billion. Despite rising coffee costs, margins expanded to the point where adjusted profitability climbed 16% to $1.08 a share. Analysts didn't have a clue, forecasting a profit of $0.94 a share with a mere 4% top-line gain.  

Ampio moved higher after Citigroup initiated coverage of the biotech with a "buy" rating. Ampio is in late-stage trials for Ampion, its anti-inflammatory treatment for osteoarthritis. Citigroup set a lofty price target of $21 on the shares.

Finally we have InterMune coming on after encouraging words out of Oppenheimer. The analyst thinks there's promise for InterMune's treatment for idiopathic pulmonary fibrosis, advising investors to buy the biotech ahead of the upcoming American Thoracic Society meeting.